Сибирский научный медицинский журнал
Cure8 research brief
Why This Matters
The paper describes a potential new anti-inflammatory/hepatoprotective candidate (a cyanobacterium extract) tested in mouse models of liver injury and IBD — early-stage research that could guide future studies but is not clinical evidence.
Who Should Pay Attention
Researchers in preclinical therapeutics, translational IBD and hepatology researchers, and clinicians interested in emerging basic-science findings.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This animal study tested whether oral administration (suspension or extract) of the cyanobacterium Leptolyngbya cf. ectocarpi affects laboratory and tissue measures in mouse models of toxic (alcohol- or acetaminophen-induced) hepatitis and dextran sulfate sodium–induced inflammatory bowel disease.
Treated mice showed changes in blood leukocyte counts, lower bilirubin and liver aminotransferases in some hepatitis models, and improvements in several microscopic features of liver and intestinal tissue compared with controls.
The study reports anti-inflammatory and hepatoprotective signals in mice, but it is a preclinical/basic-science report; it does not provide evidence about safety or effectiveness in humans.
Methods described include intragastric dosing, short treatment windows (7 days before or 30 minutes after injury), and use of standard injury models (ethanol, acetaminophen, DSS). If you are reading this as a patient: this is early laboratory research exploring a cyanobacterial extract in mice, not a ready-to-use treatment.
Do not change or stop any medical therapy based on these results and discuss any interest in experimental supplements with your clinician.
Keep In Mind
Results come from mouse models (ethanol, acetaminophen, DSS) with intragastric dosing and histologic and blood biomarker endpoints. Findings do not demonstrate human safety or efficacy; further toxicology and clinical testing would be required.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationСибирский научный медицинский журнал
PublisherInstitute of Cytology and Genetics, SB RAS
AuthorsA. P. Lykov, I. P. Uvarov, E. K. Dolgalev
Study typeJournal Article
Indexed viaCrossref
Source typeResearch paper
PublishedJul 21, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Manumycin A Attenuates DSS-Induced Colitis in Mice via Anti-Inflammatory Effects Following Intraperitoneal Administration
Researchers tested manumycin A in a standard mouse colitis model and observed reduced inflammation and tissue injury, suggesting the compound might be a candidate for further IBD drug development.
Sanggenol L Regulates Nrf2/HO-1/p65 Signalling Pathways via Dextran Sulfate Sodium-Induced Ulcerative Colitis in Mice
Researchers exploring new anti-inflammatory or antioxidant compounds for ulcerative colitis may find sanggenol L’s effects on Nrf2/HO-1 and TLR4/p65 signalling of interest. Patients should note this is early-stage,...
New coumarin-piperazine derivatives alleviate inflammatory bowel diseases as IL-6 inhibitors by targeting NF-κB pathway
The study describes new small molecules that target IL‑6 and NF‑κB and showed anti-inflammatory effects in laboratory and mouse colitis models, signaling a potential early-stage drug-discovery direction relevant to IBD...